Uterotonic Agent Mechanism

Uterotonic agent mechanism describes uterine contractility enhancement through oxytocin receptor agonism or ergot alkaloid vasconstriction. Oxytocin binds oxytocin receptors triggering myometrial contraction. Ergotamine vasconstriction increases uterine tone preventing haemorrhage. Dosing precisely controls contraction intensity. Timing optimises obstetric benefit.

Clinical monitoring assesses contraction effectiveness. Maternal safety monitoring detects hypertension from vasoconstrictors. Fetal monitoring identifies stress from excessive contractions. Regulatory submissions address mechanism selection. Post-approval surveillance identifies safety patterns.